# OnCo record nct05680922 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05680922/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05680922", "NCT05680922" ;
  schema:name "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer"@en ;
  schema:description "A phase 1 trial of LB2102 in extensive-stage small-cell lung cancer and large cell neuroendocrine carcinoma of the lung, run by Legend Biotech USA Inc, active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05680922/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05680922> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  schema:startDate "2023-07-26" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/lb2102/> ;
  onco:companies <https://onco.cc/companies/legend-biotech/> .